Integumen Share Chat (SKIN)

Find Your Broker

Share Name	Share Symbol	Market	Type	Share ISIN	Share Description
Integumen	LSE:SKIN	London	Ordinary Share	GB00BYWJ6269	ORD 0.01P

	Price Change	% Change	Share Price	Bid Price	Offer Price	High Price	Low Price	Open Price	Shares Traded	Last Trade
	+0.00p	+0.00%	0.635p	0.62p	0.65p	0.635p	0.625p	0.635p	473,134	08:04:36

Industry Sector	Turnover (m)	Profit (m)	EPS - Basic	PE Ratio	Market Cap (m)
	0.2	-9.6	5.8	0.1	2.89

Integumen Share Discussion Threads

Showing 476 to 494 of 500 messages

Chat Pages: 20 19 18 17 16 15 14 13 12 11 10 9 Older

Date	Subject	Author	Discuss
14/1/2019 08:41	373k buy early doors. Not take many more and I'm sure the mm's will get short again and run for cover and we could see 0.7p+ again	dave4545	Read Full Thread Reply
11/1/2019 10:41	@yump. A quick review of the RNS and Annual and Interim report this is what I came up with. 18 December RNS: "The Disposal will remove from the Group EUR441,000 of current liabilities and a further EUR900,000 of contractual obligations up to December 2020." Based on contractual liabilities number to December 2020, TSpro was costing EUR37.5 per month. The TSpro EUR440k (£397k) of current liabilities is an operational cost saving. From an accounting perspective, the write off of £500k TSpro intangible assets from the balance sheet will counter that saving in the 2018 accounts period. 22 November RNS: "the Company has agreed to issue 6,000,000 new Ordinary Shares (at the Issue Price) to the former Chief Executive, Mr Declan Service, together with a payment of EUR40,000. These amounts constitute the full and final settlement of amounts due to him in lieu of notice under his service and termination agreement and outstanding amounts of deferred salary and loan. This combined equity and cash consideration represent a discount to the total amounts contractually owed to Mr Service." This will balance out with shares issued for new CEO so won't add or subtract from costs. Interim Report on the 29th August: Chris Bell CFO is replaced by Camillus Glover, so costs for that post remain in place. Donald Nicholson resigned as director Helmut Schlieper resigned as director Paul Kennedy resigned as director A quick calculation with unknown, but assumed, monthly costs of £2k per director is £72k per year saving. TSpro EUR37.5k x 12 = EUR450k = (£380k) plus costs of directors fees (£72k) is £452k of annual costs removed.	mulligut	Read Full Thread Reply
10/1/2019 20:39	The first trade to sell today 105316 showing as a buy bought yesterday for 0.68p There is some serious patience in this market. Every trade today was a sale yet the price finished unchanged which shows how good this looks atm. If that volume was buying the price would have been up another 10% bio sector for small caps is a hot place to be right now...agl, mtfb, avct etc etc	dave4545	Read Full Thread Reply
10/1/2019 18:41	Yump. Assumptions come from the growth seen in the numbers of the trading update. It may be possible to consider costs from what is in the audit reports. The reduction of obligations of £1.19m for instance in TSpro may have an effect on the overhead. But that is pure speculation as the details of where that is in the £1.2m loss in the interims is beyond my ability to calculate. Unless someone with financial background knows better, this should be made clearer in the year-end report.	mulligut	Read Full Thread Reply
10/1/2019 18:01	mulligut Perhaps you could help would-be investors by explaining (as well as the revenue growth) exactly where 2mln+ of annual costs are being taken out of the business. Perhaps its been posted, but seeing as you've mentioned breakeven...and the interim loss was 1.2mln... it would seem a good idea to include the extra information...	yump	Read Full Thread Reply
10/1/2019 08:35	Mulligut, what's your target price for this undervalued share,but more Importantly how do you arrive at this figure.?	cocker	Read Full Thread Reply
10/1/2019 08:08	Buywell you certainly have been burning the midnight oil. Your comments and research clearly add value to this BB, while also shining a light on the potential of this undervalued share that is thankfully in the hands of a CEO that appears to know what he is doing. Onward and upward	mulligut	Read Full Thread Reply
09/1/2019 21:25	An unusually high level of work going in. I didn't think loss-makers were your thing but I guess they will be until you've drawn enough numpties in. Plenty of them are impressed by volume of research. That share price rise is bound to get a few buyers, as they'll be scared to miss out. Such a low share price. I mean just imagine if 0.5p eventually became £20 !!	yump	Read Full Thread Reply
09/1/2019 16:59	I go off-grid for a few hours and this happens. Nice uplift since the beginning of the year, putting strong support under the floor a few weeks back. As Buywell seems to be putting some research into what is in the trading update it is obvious that there is a lot of understated value to be realised.	mulligut	Read Full Thread Reply
09/1/2019 16:22	RE number 3 above Neuropsychopharmacology. 2018 Jan The Endogenous Cannabinoid System: A Budding Source of Targets for Treating Inflammatory and Neuropathic Pain GB some very good data here ... note tables also .... perhaps another model for AI ? hTTps://www.ncbi.nlm.nih.gov/pmc/articles/PMC5719110/ Also re 3 ................... Neuropathic pain caused by Diabetes ........................... Not many folks will have heard of that one , but with Diabetes also becoming a major Health problem for all World Health Authorities as rates increase dramatically with some countries having over 50% rates Diabetes is the leading cause of death in Mexico Another use for CBD Streptozotocin-Induced Diabetes Insulin-dependent diabetes is thought to cause one of the most prevalent forms of peripheral neuropathy in the developed world (Horowitz, 1993). Diabetic-induced neuropathic pain is difficult to treat and is generally unresponsive to current analgesic therapies. Opioids The USA is hooked on these drugs and a replacement is needed but FAST see it mentioned in the link above '' a recent meta-analysis study reported strong evidence that cannabinoids produce opioid-sparing effects in preclinical studies, but only a single study of nine clinical studies provided evidence of opioid-sparing effects in humans (Nielsen et al, 2017)'' CBD based medication looks like it to me Migraines Also mentioned in the link above Conclusions '' In sum, the endogenous cannabinoid system contains multiple promising therapeutic targets and provides a strong impetus to develop cannabinoid-based medications to treat inflammatory and neuropathic pain.''	buywell3	Read Full Thread Reply
09/1/2019 15:39	From the update CBD oil is an extract from the Cannabis Sativa plant. Cellulac (9.35% owned by Integumen) has developed a low-cost CBD oil extraction process and is collaborating with Labskin to provide a formulation for the STOER For Men range of cosmetics. Testing is underway using CBD oils of a quality comparable to that produced by Cellulac in an earlier proof of concept project. Firstly 1. Cellulac makes CBD oil 2. IMO there is going to be a need to supply CBD for medical use 3. This will probably be trans-dermal ie by skin patches 4. Surprisingly CBD has been linked with the reduction of Amyloid Beta protein in the lab ... this protein is present in the brains of many Alzheimer's sufferers. NO CURE or drug exists for Alzheimer's. 5. In the USA 1 in 3 people over the age of 65 now have Alzheimer's ( how many people knew that one ) It is increasing and costs the USA over $250 BILLION a year. Thus it is becoming a burden on the USA economy and will cost the USA OVER $1 TRILLION dollars within just over 10 years time ie it has the potential to BANKRUPT the USA ... it is only getting worse and the cost and numbers of carers keeps growing. Cannabis has had and still gets bad press ... smoking it does seem to affect the smokers brain . We all know that ... it makes you feel good as the doctor said. June 27, 2016 Cannabinoids remove plaque-forming Alzheimer’s proteins from brain cells Preliminary lab studies at the Salk Institute find THC reduces beta amyloid proteins in human neurons. hTTps://www.salk.edu/news-release/cannabinoids-remove-plaque-forming-alzheimers-proteins-from-brain-cells/ Amyloid proteotoxicity initiates an inflammatory response blocked by cannabinoids hTTps://www.nature.com/articles/npjamd201612 Hence 1. I see more Labskin testing/assays required when CBD gets to be used in newly developed drug compounds by Pharmas 2. I see Stoer CBD brand standing a good chance of increasing sales ... then who knows it might be sold to concentrate Labskin sales growth which is rocketing or become a cash cow to fund Labskin growth 3. I see CBD getting used in the treatment of Migraines , stress relief , and depression ( see below) 4. I see Cellulac producing more CBD WHAT DO CANNABINOIDS DO Cannabinoids are known to affect the user by interacting with specific receptors that are located within different parts of the central nervous system. To date two kinds of Cannabinoid receptors have been found and have been termed CB1 and CB2. In 1992 a substance that occurs naturally within the brain and binds to CB1 receptors was first discovered and termed “Anandamide.” Since then additional naturally occurring substances that bind to CB1 have been discovered, and these, along with the receptors are termed the “Endogenous Cannabinoid System.” The actual effects that the Cannabinoids have is relative to the areas of the brain they interact with. These interactions often occur in our limbic system the part of the brain that affects memory, cognition and psychomotor performance. They also occur in the mesolimbic pathway, the activity in this area is shown to be associated with feelings of well being and reward and are also widely distributed in areas of pain perception. We are still in the very early phase of learning about the Endogenous Cannabinoid System in regard to the many potential medical uses of Medicinal Cannabis.	buywell3	Read Full Thread Reply
09/1/2019 15:31	Nice rise for you guys so far today, pleased for you all.	cocker	Read Full Thread Reply
09/1/2019 12:58	philoosh Well 'its not you' as they say, but its easy enough to see posters' histories.	yump	Read Full Thread Reply
09/1/2019 12:41	0.598-0.6125p I'm pretty sure those trades earlier were buys and the price has now moved higher but if they were sales then the mm's must have a order in system.	dave4545	Read Full Thread Reply
09/1/2019 12:08	Yes thanks for that Yump. Very informative. I will value your opinion greatly.	philoosh	Read Full Thread Reply
09/1/2019 11:48	Oh look who has bought in as a punt. Well its funny how some businesses making whopping losses but with 'prospects' are worthy of doom and gloom and others are ramped. Depends on your stake I guess and its very transparent.	yump	Read Full Thread Reply
09/1/2019 11:46	For it to get back to 5p the mrk cap would be I believe around 25million & that's without the directors millions of shares yet to be issued. Near mid term 2p would represent nothing far short of a miracle.	cocker	Read Full Thread Reply
09/1/2019 11:37	So in the long term, how much is this share likely to increase? Hopefully it will get back to the 5p initial but what are everyones thoughts?	philoosh	Read Full Thread Reply
09/1/2019 07:29	Buywell, I suspect that much of what you mention was completely overlooked in the trading update. CBD related company valuations have gone through the roof with far less substantive news. According to the TU there is Stoer product with CBD and Labskin testing services for those who want to put CBD in their products.	mulligut	Read Full Thread Reply

Chat Pages: 20 19 18 17 16 15 14 13 12 11 10 9 Older

Your Recent History

LSE

SKIN

Integumen

Register now to watch these stocks streaming on the ADVFN Monitor.

Monitor lets you view up to 110 of your favourite stocks at once and is completely free to use.

By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions

ADVFN UK Investors Hub ADVFN Italy ADVFN Australia ADVFN Brazil

ADVFN Canada ADVFN Germany ADVFN Japan ADVFN Mexico

ADVFN France ADVFN US Finance Manila

P: V: D:20190119 02:24:10